NO20071403L - 4- (fenylmetyl og substituerte fenylmetyl) - imidazol-2-tioner fungerende som spesifikke alfa2 adrenergen agonister - Google Patents

4- (fenylmetyl og substituerte fenylmetyl) - imidazol-2-tioner fungerende som spesifikke alfa2 adrenergen agonister

Info

Publication number: NO20071403L
Authority: NO; Norway
Prior art keywords: phenylmethyl; compounds; adrenergic receptors; tions; imidazole
Prior art date: 2004-09-24

Application number

NO20071403A

Other languages

English (en)

Norwegian (no)

Inventor

Michael E Garst

Ken Chow

Daniel W Gil

Larry A Wheeler

Phong X Nguyen

Todd Heidelbaugh

John E Donello

Original Assignee

Allergan Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-24

Filing date

2007-03-15

Publication date

2007-05-22

2007-03-15 Application filed by Allergan Inc filed Critical Allergan Inc

2007-05-22 Publication of NO20071403L publication Critical patent/NO20071403L/no

Links

125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 title 2
239000000048 adrenergic agonist Substances 0.000 title 1
102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 abstract 5
108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 abstract 5
150000001875 compounds Chemical class 0.000 abstract 5
239000000556 agonist Substances 0.000 abstract 2
230000005792 cardiovascular activity Effects 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
230000001624 sedative effect Effects 0.000 abstract 2
241000124008 Mammalia Species 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Nutrition Science (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20071403A 2004-09-24 2007-03-15 4- (fenylmetyl og substituerte fenylmetyl) - imidazol-2-tioner fungerende som spesifikke alfa2 adrenergen agonister NO20071403L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US61292304P	2004-09-24	2004-09-24
PCT/US2005/031790 WO2006036480A1 (en)	2004-09-24	2005-09-07	4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists

Publications (1)

Publication Number	Publication Date
NO20071403L true NO20071403L (no)	2007-05-22

Family

ID=35559467

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20071403A NO20071403L (no)	2004-09-24	2007-03-15	4- (fenylmetyl og substituerte fenylmetyl) - imidazol-2-tioner fungerende som spesifikke alfa2 adrenergen agonister

Country Status (17)

Country	Link
US (1)	US7683089B1 (pt)
EP (1)	EP1797043A1 (pt)
JP (1)	JP2008514601A (pt)
KR (1)	KR20070054213A (pt)
CN (1)	CN101031549A (pt)
AR (1)	AR051107A1 (pt)
AU (1)	AU2005290075A1 (pt)
BR (1)	BRPI0516083A (pt)
CA (1)	CA2581579A1 (pt)
IL (1)	IL181749A0 (pt)
MX (1)	MX2007003068A (pt)
NO (1)	NO20071403L (pt)
NZ (1)	NZ553341A (pt)
RU (2)	RU2383535C2 (pt)
TW (1)	TW200626147A (pt)
WO (1)	WO2006036480A1 (pt)
ZA (1)	ZA200701427B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2008130448A (ru) *	2006-01-27	2010-03-10	Ф. Хоффманн-Ля Рош Аг (Ch)	Применение производных 4-имидазола для расстройств цнс
EP1918282A1 (en) *	2006-11-06	2008-05-07	"Joint Stock Company Grindeks"	Method for preparing medetomidine and its salts
WO2009052072A1 (en) *	2007-10-18	2009-04-23	Allergan, Inc.	Treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
US8455548B2 (en) *	2007-10-18	2013-06-04	Allergan, Inc.	Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
AU2010213649A1 (en) *	2009-02-13	2011-09-08	Allergan, Inc.	4-(1-(3-(hydroxymethyl)-2-methylphenyl)ethyl)-1H-imidazole-2(3H)-thione
EP2605771B1 (en) *	2010-08-16	2018-04-04	Allergan, Inc.	Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists
US8653123B2 (en) *	2010-09-16	2014-02-18	Allergan, Inc.	Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
EP2782569A1 (en)	2011-11-21	2014-10-01	Allergan, Inc.	Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
CN105884691B (zh) *	2016-06-02	2017-08-25	江苏恒瑞医药股份有限公司	一种制备右美托咪定及其中间体的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SU795462A3 (ru)	1975-03-14	1981-01-07	Эдьт Дьедьесерведьесети Дьяр (Фирма)	Способ получени тиокарбамидныхпРОизВОдНыХ
US4798843A (en) *	1987-07-09	1989-01-17	Smithkline Beckman Corporation	2-mercaproimidazole dopamine-β-hydroxylase inhibitors
JPH0667368A (ja)	1992-08-13	1994-03-11	Fuji Photo Film Co Ltd	黒白ハロゲン化銀写真感光材料の現像方法
ZA971896B (en)	1996-03-26	1998-09-07	Du Pont Merck Pharma	Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives
WO1997049704A1 (en)	1996-06-27	1997-12-31	Janssen Pharmaceutica N.V.	N-[4-(heteroarylmethyl)phenyl]-heteroarylamines
WO1999028200A1 (en)	1997-11-28	1999-06-10	Mitsubishi Plastics, Inc.	Handle for plastic bottles and handle-carrying plastic bottle
PT1036065E (pt) *	1997-12-04	2004-09-30	Allergan Inc	Derivados de imidazol substituidos com actividade do tipo agonista nos receptores alfa 2b ou 2b/2c adrenergicos
US6841684B2 (en) *	1997-12-04	2005-01-11	Allergan, Inc.	Imidiazoles having reduced side effects
TWI283669B (en) *	1999-06-10	2007-07-11	Allergan Inc	Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
AU5704000A (en) *	1999-06-28	2001-01-31	Meiji Seika Kaisha Ltd.	Hydrazone derivatives and pest controllers
JP2002097310A (ja)	2000-09-25	2002-04-02	Bridgestone Corp	タイヤ
JP2002097312A (ja)	2000-09-26	2002-04-02	Bridgestone Corp	タイヤ
WO2002058730A2 (en)	2000-11-01	2002-08-01	Allergan, Inc.	Compositions for treatment of ocular neovascularization
CN100338074C (zh) *	2001-01-30	2007-09-19	全药工业株式会社	杂环化合物和以其为有效成分的脑机能改善剂
EP1379241A1 (en) *	2001-03-29	2004-01-14	SmithKline Beecham Corporation	Compounds and methods
US7345065B2 (en) *	2002-05-21	2008-03-18	Allergan, Inc.	Methods and compositions for alleviating pain
US7091232B2 (en) *	2002-05-21	2006-08-15	Allergan, Inc.	4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7323485B2 (en) *	2002-05-21	2008-01-29	Allergan, Inc.	4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7141597B2 (en) *	2003-09-12	2006-11-28	Allergan, Inc.	Nonsedating α-2 agonists
US20050059664A1 (en) *	2003-09-12	2005-03-17	Allergan, Inc.	Novel methods for identifying improved, non-sedating alpha-2 agonists

2005
- 2005-09-07 CN CNA2005800322112A patent/CN101031549A/zh active Pending
- 2005-09-07 MX MX2007003068A patent/MX2007003068A/es not_active Application Discontinuation
- 2005-09-07 KR KR1020077006529A patent/KR20070054213A/ko not_active Withdrawn
- 2005-09-07 AU AU2005290075A patent/AU2005290075A1/en not_active Abandoned
- 2005-09-07 EP EP05796203A patent/EP1797043A1/en not_active Withdrawn
- 2005-09-07 NZ NZ553341A patent/NZ553341A/en unknown
- 2005-09-07 BR BRPI0516083-9A patent/BRPI0516083A/pt not_active IP Right Cessation
- 2005-09-07 CA CA002581579A patent/CA2581579A1/en not_active Abandoned
- 2005-09-07 RU RU2007110711/04A patent/RU2383535C2/ru not_active IP Right Cessation
- 2005-09-07 JP JP2007533510A patent/JP2008514601A/ja active Pending
- 2005-09-07 WO PCT/US2005/031790 patent/WO2006036480A1/en not_active Ceased
- 2005-09-20 US US11/232,341 patent/US7683089B1/en not_active Expired - Fee Related
- 2005-09-23 TW TW094133103A patent/TW200626147A/zh unknown
- 2005-09-26 AR ARP050103994A patent/AR051107A1/es not_active Application Discontinuation
2007
- 2007-02-19 ZA ZA200701427A patent/ZA200701427B/xx unknown
- 2007-03-06 IL IL181749A patent/IL181749A0/en unknown
- 2007-03-15 NO NO20071403A patent/NO20071403L/no not_active Application Discontinuation
2009
- 2009-11-13 RU RU2009141800/04A patent/RU2009141800A/ru not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2581579A1 (en)	2006-04-06
MX2007003068A (es)	2007-05-21
AU2005290075A1 (en)	2006-04-06
AR051107A1 (es)	2006-12-20
KR20070054213A (ko)	2007-05-28
US7683089B1 (en)	2010-03-23
BRPI0516083A (pt)	2008-08-19
CN101031549A (zh)	2007-09-05
NZ553341A (en)	2010-11-26
JP2008514601A (ja)	2008-05-08
TW200626147A (en)	2006-08-01
EP1797043A1 (en)	2007-06-20
RU2009141800A (ru)	2011-05-20
IL181749A0 (en)	2007-07-04
ZA200701427B (en)	2008-08-27
RU2383535C2 (ru)	2010-03-10
RU2007110711A (ru)	2008-10-27
WO2006036480A1 (en)	2006-04-06

Legal Events

Date	Code	Title	Description
2012-04-30	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20071403L (no)	2007-05-22	4- (fenylmetyl og substituerte fenylmetyl) - imidazol-2-tioner fungerende som spesifikke alfa2 adrenergen agonister
MA31167B1 (fr)	2010-02-01	Inhibiteurs de l'activite de akt
PH12021550882A1 (en)	2022-02-21	Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
MA32611B1 (fr)	2011-09-01	Procedes de traitement de la thalassemie
EA200900828A1 (ru)	2009-12-30	Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
NO20061074L (no)	2006-03-06	Forbindelser og sammensetninger som inbibitorer av reseptortyrosinkinaseaktivitet
NO20083568L (no)	2008-10-16	Hydantoinforbindelser for behandling av inflammatoriske forstyrrelser
NO20081482L (no)	2008-05-16	Delta- og epsilon-krystallformer for imatinibmesylat
TW200624430A (en)	2006-07-16	4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
TW200626146A (en)	2006-08-01	4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
NO20082939L (no)	2008-09-17	Sykloheksyl piperasinyl metanon derivater og anvendelse av disse som histamin H3 reseptor modulatorer
ATE534632T1 (de)	2011-12-15	Thiazole, imidazole und pyrazole als proteinkinasehemmer
BR112017015487A2 (pt)	2018-01-30	Composto; composição; método de tratamento e/ou prevenção de enxaqueca, als, doença de alzheimer, doença de parkinson, distúrbios extrapirimidais, depressão, náusea, êmese, síndrome das pernas inquietas, insônia, agressão, doença de huntington, doença cardiopulmonar, fibrogênese, hipertensão arterial pulmonar, ansiedade, dependências a drogas, distonia, parassonia ou hiperlactinemia em um indivíduo; métodos de agonização dos receptores d2, 5-ht1d, 5-ht1a e 5-ht2c, em um indivíduo; método de antagonização do receptor d3 em um indivíduo; métodos de agonização seletiva dos receptores 5 -ht1d, e 5-ht2c, método de fornecimento de atividade de antagonista funcional no receptor 5 -ht2b ou no receptor 5-ht7, ou em ambos, em um indivíduo; método de fornecimento de atividade de antagonista funcional nos receptores adrenérgicos em um indivíduo
EP2563794A4 (en)	2013-12-04	INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY AND ITS USE FOR THE TREATMENT OF EYE DISEASES
MA38810B1 (fr)	2018-06-29	Inhibiteurs de rorc2 méthodes d'utilisation associées
ATE430743T1 (de)	2009-05-15	Benzimidazolsubstituierte thiophenderivate, die auf ikk3 wirken
BR112014012479A2 (pt)	2017-06-06	derivados de [1,2,3]triazol[4,5-d]pirimidina como agonistas das agonistas de receptor 2 de canabinóide
BRPI0511527A (pt)	2008-01-02	compostos e composições como moduladores de ppar
CA3242701A1 (en)	2023-07-13	Treatment of gm2 gangliosidosis
NO20065678L (no)	2007-02-08	3-(4-heteroarylcykloheksylamino) cyklopentankarboksamider som modulatorer for kjemokinreseptorer.
BRPI0411095A (pt)	2006-07-18	derivados de imidazol
BRPI0507120A (pt)	2007-06-19	compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
FR2942720B1 (fr)	2024-01-19	Utilisation cosmetique d'hesperidine.
UA88165C2 (xx)	2009-09-25	Застосування тризаміщених бензопіранонів$применение трехзамещенных бензопиранонов
MA31902B1 (fr)	2010-12-01	Oxazolidinones pour le traitement et/ou la prophylaxie de l'insuffisance cardiaque